Indian company Lupin Ltd announced today that its subsidiary, Lupin Pharmaceutical Inc has received approval from the United States Food and Drug Administration (USFDA) to market a generic version of Lyrica (Pregabalin) capsules. The drug is used to treat pain associated with the effects on the nerves due to diabetes, herpes and fibromyalgia. LYRICA had annual U.S sales of approximately $1.8 billion for the twelve months ending March 2012 (IMS Health Sales Data).
This is not the first instance of an Indian company launching a generic drug in the US market.
Earlier Dr Reddy’s launched two generic drugs – a generic version of Roche’s anti-osteoporosis drug and another for acidity and heartburn – whereas Sun pharma launched a nasal spray for allergic rhinitis in the USA.